Search

Your search keyword '"Nomdedeu, Josep"' showing total 22 results
Start Over Author "Nomdedeu, Josep" Publisher wiley
22 results on '"Nomdedeu, Josep"'

1. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

Author

Mosquera Orgueira, Adrian, primary, Perez Encinas, Manuel Mateo, additional, Diaz Varela, Nicolas, additional, Wang, Yu‐Hung, additional, Mora, Elvira, additional, Diaz‐Beya, Marina, additional, Montoro, Maria Julia, additional, Pomares Marin, Helena, additional, Ramos Ortega, Fernando, additional, Tormo, Mar, additional, Jerez, Andres, additional, Nomdedeu, Josep, additional, de Miguel Sanchez, Carlos, additional, Arenillas, Leonor, additional, Carcel, Paula, additional, Cedena Romero, Maria Teresa, additional, Xicoy Cirici, Blanca, additional, Rivero Arango, Eugenia, additional, Del Orbe Barreto, Rafael Andrés, additional, Benlloch, Luis, additional, Lin, Chien‐Chin, additional, Tien, Hwei‐Fang, additional, Pérez Míguez, Carlos, additional, Crucitti, Davide, additional, Díez Campelo, María, additional, and Valcárcel, David, additional

Published
2024
Full Text
View/download PDF

2. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high‐hyperdiploid B‐cell acute lymphoblastic leukemia

Author

Ramos‐Muntada, Mireia, primary, Trincado, Juan L., additional, Blanco, Joan, additional, Bueno, Clara, additional, Rodríguez‐Cortez, Virginia C., additional, Bataller, Alex, additional, López‐Millán, Belén, additional, Schwab, Claire, additional, Ortega, Margarita, additional, Velasco, Pablo, additional, Blanco, Maria L., additional, Nomdedeu, Josep, additional, Ramírez‐Orellana, Manuel, additional, Minguela, Alfredo, additional, Fuster, Jose L., additional, Cuatrecasas, Esther, additional, Camós, Mireia, additional, Ballerini, Paola, additional, Escherich, Gabriele, additional, Boer, Judith, additional, DenBoer, Monique, additional, Hernández‐Rivas, Jesús M., additional, Calasanz, Maria J., additional, Cazzaniga, Giovanni, additional, Harrison, Christine J., additional, Menéndez, Pablo, additional, and Molina, Oscar, additional

Published
2022
Full Text
View/download PDF

3. Author response for 'Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia'

Author

null Ramos-Muntada, Mireia, null Trincado, Juan L., null Blanco, Joan, null Bueno, Clara, null Rodriguez-Cortez, Virginia C., null Bataller, Alex, null Lopez-Millan, Belen, null Schwab, Claire, null Ortega, Margarita, null Velasco, Pablo, null Blanco, Maria L., null Nomdedeu, Josep, null Ramirez-Orellana, Manuel, null Minguela, Alfredo, null Fuster, Jose L., null Cuatrecasas, Esther, null Camos, Mireia, null Ballerini, Paola, null Escherich, Gabriele, null Boer, Judith, null DenBoer, Monique, null Hernandez-Rivas, Jesus M., null Calasanz, Maria J., null Cazzaniga, Giovanni, null Harrison, Christine J., null Menendez, Pablo, and null Molina, Oscar

Published
2022
Full Text
View/download PDF

5. The Landscape of KMT2A-PTD AML

Author

Hinai, Adil Al, primary, Pratcorona, Marta, additional, Grob, Tim, additional, Kavelaars, François G., additional, Bussaglia, Elena, additional, Sanders, Mathijs A., additional, Nomdedeu, Josep, additional, and Valk, Peter J.M., additional

Published
2019
Full Text
View/download PDF

7. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Author

Rawstron, Andy C., Kreuzer, Karl-Anton, Soosapilla, Asha, Spacek, Martin, Stehlikova, Olga, Gambell, Peter, McIver-Brown, Neil, Villamor, Neus, Psarra, Katherina, Arroz, Maria, Milani, Raffaella, de la Serna, Javier, Teresa Cedena, M., Jaksic, Ozren, Nomdedeu, Josep, Moreno, Carol, Rigolin, Gian Matteo, Cuneo, Antonio, Johansen, Preben, Johnsen, Hans E., Rosenquist, Richard, Niemann, Carsten Utoft, Kern, Wolfgang, Westerman, David, Trneny, Marek, Mulligan, Stephen, Doubek, Michael, Pospisilova, Sarka, Hillmen, Peter, Oscier, David, Hallek, Michael, Ghia, Paolo, Montserrat, Emili, Rawstron, Andy C., Kreuzer, Karl-Anton, Soosapilla, Asha, Spacek, Martin, Stehlikova, Olga, Gambell, Peter, McIver-Brown, Neil, Villamor, Neus, Psarra, Katherina, Arroz, Maria, Milani, Raffaella, de la Serna, Javier, Teresa Cedena, M., Jaksic, Ozren, Nomdedeu, Josep, Moreno, Carol, Rigolin, Gian Matteo, Cuneo, Antonio, Johansen, Preben, Johnsen, Hans E., Rosenquist, Richard, Niemann, Carsten Utoft, Kern, Wolfgang, Westerman, David, Trneny, Marek, Mulligan, Stephen, Doubek, Michael, Pospisilova, Sarka, Hillmen, Peter, Oscier, David, Hallek, Michael, Ghia, Paolo, and Montserrat, Emili

Abstract

The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as required or recommended for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate required markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5-20 in 82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for required diagnostic markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. Recommended markers potentially useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible criteria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and showed >97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as required for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus recommended panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. (c) 2017 International Clinical Cytometry Society

Published
2018

8. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Author

Rawstron, Andy C., primary, Kreuzer, Karl-Anton, additional, Soosapilla, Asha, additional, Spacek, Martin, additional, Stehlikova, Olga, additional, Gambell, Peter, additional, McIver-Brown, Neil, additional, Villamor, Neus, additional, Psarra, Katherina, additional, Arroz, Maria, additional, Milani, Raffaella, additional, de la Serna, Javier, additional, Cedena, M. Teresa, additional, Jaksic, Ozren, additional, Nomdedeu, Josep, additional, Moreno, Carol, additional, Rigolin, Gian Matteo, additional, Cuneo, Antonio, additional, Johansen, Preben, additional, Johnsen, Hans E., additional, Rosenquist, Richard, additional, Niemann, Carsten Utoft, additional, Kern, Wolfgang, additional, Westerman, David, additional, Trneny, Marek, additional, Mulligan, Stephen, additional, Doubek, Michael, additional, Pospisilova, Sarka, additional, Hillmen, Peter, additional, Oscier, David, additional, Hallek, Michael, additional, Ghia, Paolo, additional, and Montserrat, Emili, additional

Published
2018
Full Text
View/download PDF

9. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease

Author

Hoyos, Montserrat, primary, Nomdedeu, Josep F., additional, Esteve, Jordi, additional, Duarte, Rafael, additional, Ribera, Josep M., additional, Llorente, Andreu, additional, Escoda, Lourdes, additional, Bueno, Javier, additional, Tormo, Mar, additional, Gallardo, David, additional, de Llano, Maria Paz Queipo, additional, Martí, Josep M., additional, Aventín, Anna, additional, Mangues, Ramón, additional, Brunet, Salut, additional, and Sierra, Jorge, additional

Published
2013
Full Text
View/download PDF

10. Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome

Author

Chigrinova, Ekaterina, primary, Mian, Michael, additional, Scandurra, Marta, additional, Greiner, Timothy C., additional, Chan, Wing C., additional, Vose, Julie M., additional, Inghirami, Giorgio, additional, Chiappella, Annalisa, additional, Baldini, Luca, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Franceschetti, Silvia, additional, Gaidano, Gianluca, additional, Tucci, Alessandra, additional, Facchetti, Fabio, additional, Lazure, Thierry, additional, Lambotte, Olivier, additional, Montes‐Moreno, Santiago, additional, Piris, Miguel A., additional, Nomdedeu, Josep Fr., additional, Uccella, Silvia, additional, Rancoita, Paola M.V., additional, Kwee, Ivo, additional, Zucca, Emanuele, additional, and Bertoni, Francesco, additional

Published
2011
Full Text
View/download PDF

11. Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21

Author

Scandurra, Marta, primary, Mian, Michael, additional, Greiner, Timothy C., additional, Rancoita, Paola M. V., additional, De Campos, Cassio P., additional, Chan, Wing C., additional, Vose, Julie M., additional, Chigrinova, Ekaterina, additional, Inghirami, Giorgio, additional, Chiappella, Annalisa, additional, Baldini, Luca, additional, Ponzoni, Maurilio, additional, Ferreri, Andres J.M., additional, Franceschetti, Silvia, additional, Gaidano, Gianluca, additional, Montes‐Moreno, Santiago, additional, Piris, Miguel A., additional, Facchetti, Fabio, additional, Tucci, Alessandra, additional, Nomdedeu, Josep Fr., additional, Lazure, Thierry, additional, Lambotte, Olivier, additional, Uccella, Silvia, additional, Pinotti, Graziella, additional, Pruneri, Giancarlo, additional, Martinelli, Giovanni, additional, Young, Ken H., additional, Tibiletti, Maria Grazia, additional, Rinaldi, Andrea, additional, Zucca, Emanuele, additional, Kwee, Ivo, additional, and Bertoni, Francesco, additional

Published
2010
Full Text
View/download PDF

12. Beta2‐microglobulin is a better predictor of treatment‐free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate

Author

Delgado, Julio, primary, Pratt, Guy, additional, Phillips, Neil, additional, Briones, Javier, additional, Fegan, Chris, additional, Nomdedeu, Josep, additional, Pepper, Chris, additional, Aventin, Anna, additional, Ayats, Ramon, additional, Brunet, Salut, additional, Martino, Rodrigo, additional, Valcarcel, David, additional, Milligan, Donald, additional, and Sierra, Jorge, additional

Published
2009
Full Text
View/download PDF

16. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia

Author

Gaidano, Gianluca, primary, Pastore, Cristina, additional, Santini, Valeria, additional, Nomdedeu, Josep, additional, Gamberi, Barbara, additional, Capello, Daniela, additional, Vischia, Federico, additional, Resegotti, Luigi, additional, Mazza, Umberto, additional, Ferrini, Pierluigi Rossi, additional, Lo Coco, Francesco, additional, and Saglio, Giuseppe, additional

Published
1997
Full Text
View/download PDF

17. Distribution ofTP53 mutations among acute leukemias withMLL rearrangements

Author

Lanza, Carlo, primary, Gaidano, Gianluca, additional, Cimino, Giuseppe, additional, Pastore, Cristina, additional, Nomdedeu, Josep, additional, Volpe, Gisella, additional, Vivenza, Claudia, additional, Parvis, Guido, additional, Mazza, Umberto, additional, Basso, Giuseppe, additional, Madon, Enrico, additional, Lo Coco, Francesco, additional, and Saglio, Giuseppe, additional

Published
1996
Full Text
View/download PDF

21. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.

Author

Mosquera Orgueira A, Perez Encinas MM, Diaz Varela NA, Mora E, Díaz-Beyá M, Montoro MJ, Pomares H, Ramos F, Tormo M, Jerez A, Nomdedeu JF, De Miguel Sanchez C, Leonor A, Cárcel P, Cedena Romero MT, Xicoy B, Rivero E, Del Orbe Barreto RA, Diez-Campelo M, Benlloch LE, Crucitti D, and Valcárcel D

Abstract

Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of acute leukemia. As prognosis differs widely between patients, and treatment options vary from observation to allogeneic stem cell transplantation, accurate and precise disease risk prognostication is critical for decision making. With this aim, we retrieved registry data from MDS patients from 90 Spanish institutions. A total of 7202 patients were included, which were divided into a training (80%) and a test (20%) set. A machine learning technique (random survival forests) was used to model overall survival (OS) and leukemia-free survival (LFS). The optimal model was based on 8 variables (age, gender, hemoglobin, leukocyte count, platelet count, neutrophil percentage, bone marrow blast, and cytogenetic risk group). This model achieved high accuracy in predicting OS (c-indexes; 0.759 and 0.776) and LFS (c-indexes; 0.812 and 0.845). Importantly, the model was superior to the revised International Prognostic Scoring System (IPSS-R) and the age-adjusted IPSS-R. This difference persisted in different age ranges and in all evaluated disease subgroups. Finally, we validated our results in an external cohort, confirming the superiority of the Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS) over the IPSS-R, and achieving a similar performance as the molecular IPSS. In conclusion, the AIPSS-MDS score is a new prognostic model based exclusively on traditional clinical, hematological, and cytogenetic variables. AIPSS-MDS has a high prognostic accuracy in predicting survival in MDS patients, outperforming other well-established risk-scoring systems., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Published
2023
Full Text
View/download PDF

22. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.

Author

Ribera J, Morgades M, Zamora L, Montesinos P, Gómez-Seguí I, Pratcorona M, Sarrà J, Guàrdia R, Nomdedeu J, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, González-Campos J, Barba P, Escoda L, Genescà E, Solé F, Millá F, Feliu E, and Ribera JM

Subjects
Acute Disease, Adolescent, Adult, Aged, Cyclin-Dependent Kinase Inhibitor p15 genetics, Cyclin-Dependent Kinase Inhibitor p16 genetics, Female, Humans, Ikaros Transcription Factor genetics, Male, Middle Aged, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Prognosis, Spain, Survival Rate, Trans-Activators genetics, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, DNA Copy Number Variations genetics, Gene Deletion, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics
Abstract

Background: Some copy number alterations (CNAs) have independent prognostic significance for adults with acute lymphoblastic leukemia (ALL)., Methods: This study analyzed via multiplex ligation-dependent probe amplification the frequency and prognostic impact of CNAs of 12 genetic regions in 142 adolescents and adults with de novo precursor B-cell ALL., Results: The cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion (59 of 142 or 42%) was the most frequent CNA, and it was followed by Ikaros family zinc finger 1 (IKZF1) losses (49 of 142 or 35%). IKZF1 deletions were more prevalent in Philadelphia chromosome (Ph)-positive ALL and were associated with advanced age and high white blood cell (WBC) counts. The multivariate analysis showed that advanced age and early B-cell factor 1 (EBF1) deletions were associated with chemotherapy resistance in both the whole series (hazard ratios, 0.949 and 0.135, respectively) and the Ph-negative subgroup (hazard ratios, 0.946 and 0.118, respectively). High WBC counts and focal IKZF1 deletions correlated with disease recurrence (hazard ratios, 1.005 and 1.869, respectively), whereas advanced age and CDKN2A/B losses influenced overall survival in both the whole series (hazard ratios, 1.038 and 2.545, respectively) and the Ph-negative subgroup (hazard ratios, 1.044 and 2.105, respectively)., Conclusions: Deletions of EBF1, IKZF1, and CDKN2A/B have an independent adverse prognosis for adolescents and adults with B-precursor ALL, and this suggests that these CNAs should be included in the initial risk assessment of ALL., (© 2015 American Cancer Society.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results